Charles Schwab
ARTV

Charles Schwab’s Artiva Biotherapeutics ARTV Stock Holding History

Charles Schwab’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-54,881
Closed -$165K – 3604
2025
Q1 		$165K Buy
54,881
+11,355
+26% +$61.3K ﹤0.01% 3279
2024
Q4 		$439K Buy
43,526
+3,233
+8% +$38.8K ﹤0.01% 3184
2024
Q3 		$623K Buy
+40,293
New +$467K ﹤0.01% 3082

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Charles Schwab's ARTV Position: Q2 2025 in Review

Charles Schwab sold out of Artiva Biotherapeutics (ARTV) in Q2 2025, closing a stake of 54,881 shares — an estimated $165K sold.

Charles Schwab first reported a position in ARTV in Q3 2024 and held it in 3 quarters. The position peaked at $623K in Q3 2024. 48 funds tracked by Wall St. Rank hold ARTV as of Q2 2025.

  • Charles Schwab reported no remaining Artiva Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Charles Schwab sold 54,881 Artiva Biotherapeutics shares in Q2 2025, an estimated $165K.
  • Charles Schwab first reported a position in Artiva Biotherapeutics in Q3 2024 and held it in 3 quarters.
  • Charles Schwab's Artiva Biotherapeutics position peaked at $623K in Q3 2024.
  • 48 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2025.

Based on Charles Schwab's 13F filing for Q2 2025, filed 12 Aug 2025.